In this article, we review the current knowledge of the link between GBA1 and PD risk; review the clinical features associated with GBA1 variants; discuss the practicalities of GBA1 testing, which is impacted by its pseudogene; and lastly advise how to communicate the risk to index cases and their families. The gene discussed is GBA1; the disease is Parkinson disease.